Precision Oncology Laboratory: “giving the right drugs, to the right patient, at the right time”

Overall goal of the DasGupta lab is to implement the next-generation functional genomic technologies on individualised patient-derived models to query novel genetic and therapeutic vulnerabilities in solid cancers. The major research focus is to establish novel 'Precision Oncology' platforms (such as patient-derived tumor organoids and primary cancer cell lines) that can be used to: a) study the impact of tumor heterogeneity on the evolutionary mechanisms of tumour metastasis and treatment-resistance; b) identify novel transcriptomic/epigenetic biomarkers of treatment response and tumor progression; c) identify novel therapeutic targets and drug candidates for the precision targeting of specific oncogenic pathways and immune-modulatory response; d) dissect the function of the tumor microenvironment in modulating response to chemo/targeted therapies and immune-oncology drugs.

The DasGupta lab uses a variety of genomic tools to address these questions, including single cell and bulk-transcriptomics, epigenomics, and functional/chemical genomic tools, such as high-throughput/high-content screening (HTS/HCS) technologies.
Additionally, the DasGupta lab is also interested in the identification and functional characterization of non-coding RNAs (ncRNAs), especially lncRNAs and tRNA-derived small RNAs (tsRNAs) in the control of cancer stem cells, oncogenic pathways and embryonic stem cell biology.


Major focus in the DasGupta lab is to investigate the role of intra-tumor heterogeneity (ITH) and cancer stem cells (CSCs) in tumor metastasis and evolution of treatment resistance: We are employing structural and functional genomic approaches to identify drivers of metastasis and chemo-resistance in patient-derived in vitro organoid and in vivo xenograft models of colorectal, oral and breast cancers (Chia, Low et al., Nat Comm., 2017; Tan et al., Nat Med 2017). In parallel, we are uncovering novel therapeutic targets as well as therapeutic/drug combinations that can preferentially target the destruction of resistant or metastatic cancer cells. Using genomic characterization of patient-derived tumor models, we are developing novel prediction algorithms to predict sensitivity to standard-of-care drugs (Chia, Low et al., Nat Comm., 2017; Tan et al., Nat Med 2017). In separate studies, we have focused on identifying therapeutic vulnerabilities in TKI-resistant HSNCC that are wild type for T790M, a common mutation associated with resistance against TKIs. Finally, we are collaborating with Dr. Hao Fan’s lab at the BII to identify novel small molecule inhibitors of Wnt-b-catenin signaling using in silico screening and in vitro/in vivo validation assays (Low et al., 2018, manuscript in preparation).

We are using single cell genomic technologies to characterise the function/impact of intra-tumor heterogeneity in tumor progression towards metastatic and treatment resistant disease. We do so by employing single cell RNA-seq to map the trajectories of individual cells as they evolve under the selection pressure of drugs and/or metastasis, and investigate the role of clonal/Darwinian selection, epigenetic plasticity and adaptation in tumor progression (Sharma et al., 2018 manuscript in preparation). Additionally we are exploring the function of epigenetic regulation in modulation of specific gene signatures to identify upstream drivers of metastatic and resistant phenotypes. We have also initiated single cell RNA-seq to understand ITH in HCC and breast cancers in order to identify how the tumor microenvironment (TME), including the immune/stromal environment, changes upon treatment with cancer drugs. Additionally we are building capacity for single cell ATAC-seq to investigate epigenetic heterogeneity and plasticity during tumor evolution under selection pressure of drugs and/or metastasis.

3. Non-coding RNAs in STEM CELL and WNT BIOLOGY
The second major focus in the lab is the identification and characterization of novel miRNAs, lncRNAs and small non-coding RNAs that inhibit Wnt/ß-catenin-responsive transcription (CRT), as well as modulate activity of known oncogenic signaling pathways (Saj et al Stem Cells, 2017): Additionally, at the GIS, we are characterizing the function of several novel small RNAs that are differentially expressed/regulated in stem versus differentiating ES cells, as well as in cancer stem cells (CSCs) (Krishna, Yim et al., under review 2018). In the near future we will expand this program into cancer cells in collaboration with Dr. Wan Yue’s lab (GIS) by investigating the function of tsRNA-interactome in regulating cell states.

The DasGupta lab is also developing novel tools and technologies to generate monobody-based biosensors against treatment-resistant cancer stem cells, and metastasis-initiating cells developed from the patient-derived models generated in the lab. We have already generated a library of binders against key oncogenic proteins such as ß-catenin (Sci Rep., 2013) and Notch-1 (Gocha et al., Scientific Reports., 2017). We are expanding the scaffold-based screen to identify and target the activity of immune cells in the tumor microenvironment that can be used to modulate response to immunotherapy.


  • 1994-96 Cambridge Commonwealth Trust/Cambridge-Nehru Award, Cambridge, UK

    1996-2000 Markey Fellowship on Molecular Medicine, University of Chicago, USA

    2001 Harold Weintraub Graduate Student Award, Fred Hutchinson Cancer Center, Seattle, WA USA

    2003-2005 Breast Cancer Research Foundation Postdoctoral award, Department of Defense, USA

    2007-2008 Concept Award, Department of Defense

    2009-2010 NYSTEM Idea Award, New York, USA

    2010-2013 March of Dimes Research Scholar grant, USA

    2011-2015 American Cancer Society Research Scholar Grant, USA

    2012-2014 NYC Bioaccelerate Prize, New York, NY USA

Main Menu